Sanofi Shares Hit a 6-Year Low at €74.21, Under Pressure
On Tuesday, Sanofi shares recorded a new six-year low during the session, dropping to €74.21, a level not seen since the Covid-19 crash of 2020. By midday, however, the stock had recovered by 0.99% to €74.42, amidst a CAC 40 increase of 0.61%. The company continues to be affected by a downgrade from Morgan Stanley published the previous day.
A Six-Year Low Following Morgan Stanley's Downgrade
The intraday drop to €74.21 erases the previous low of €74.85, reached during the health crisis in 2020. Sanofi has lost 5.68% over the week and 24% over the year. This movement follows the downgrade by Morgan Stanley from overweight to equal weight, with a price target reduced from €95 to €90. Based on the current price, the new target still represents a gap of about 16%, placing the consensus outlook in a zone of renewed caution. The 0.99% rebound at midday comes after several sessions of continuous decline, in a rising Paris market.
Below the Lower Bollinger Band, Support at €76.83 Breached
The share price is now trading below the lower Bollinger band set at €77.90, a rare oversold configuration for the stock. It has also broken through its identified support at €76.83, with a gap of more than 3% below this level. The RSI at 41 remains neutral, indicating that the downward movement has not yet reached a seller exhaustion zone. Sanofi is trading 6.5% below its 50-day moving average (€79.59) and nearly 10% below its 200-day moving average (€82.32), confirming a break from the medium-term trend. Despite this, in the first quarter of 2026, the company had reported a 13.6% increase in sales at constant exchange rates and a 14% increase in earnings per share from operations. The next key date is the second quarter results, expected on July 30.
